Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Carolyn Davidson

Nurse Practitioner, Psychiatric/Mental Health Milwaukee, WI Nurse Practitioner

NPI 1043440480 CMS profile 10794857

10242 Bluemound Rd, Milwaukee, WI 53226

Open in the dashboard

General payments

$45,784

595 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Carolyn Davidson of Milwaukee, WI is reported in the CMS Open Payments database as having received $45,784 across 595 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,656 192
2024 General $9,496 135
2023 General $16,591 127
2022 General $3,980 56
2021 General $5,060 85

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Carolyn Davidson
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Carolyn Davidson were reported at $10,656. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Carolyn Davidson Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $5,060 $166 $54–$482 $132
2022 $3,980 $195 $66–$559 $149
2023 $16,591 $233 $82–$673 $160
2024 $9,496 $236 $84–$688 $164
2025 $10,656 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $30,515 138 payments
  2. Teva Pharmaceuticals USA, Inc. $6,305 37 payments
  3. Alkermes, Inc. $1,199 55 payments
  4. Otsuka America Pharmaceutical, Inc. $1,191 44 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $946 56 payments
  6. Axsome Therapeutics, Inc. $862 31 payments
  7. Neurocrine Biosciences, Inc. $718 28 payments
  8. Vanda Pharmaceuticals Inc. $700 44 payments
  9. Corium, Inc. $520 28 payments
  10. Lundbeck LLC $477 27 payments
  11. Other $2,350 107 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $33,375 27 payments
  2. Food and Beverage $11,768 553 payments
  3. Travel and Lodging $437 4 payments
  4. Education $204 11 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $23,169 108 payments
  2. VRAYLAR Neuroscience $7,329 29 payments
  3. UZEDY $5,444 11 payments
  4. LYBALVI $1,079 54 payments
  5. ARISTADA Cns $933 51 payments
  6. ARISTADA Cns $933 51 payments
  7. REXULTI $921 40 payments
  8. ARISTADA Cns $864 42 payments
  9. ARISTADA Cns $864 42 payments
  10. Auvelity $862 31 payments
  11. Other $8,225 364 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 55 drugs

Part D claims

3,969

Median for Nurse Practitioner: 389

Drug cost

$492,127

Median for Nurse Practitioner: $21,885

Branded share of claims

24.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 119 $185,293
Austedo Deutetrabenazine Brand 18 $132,642
Caplyta Lumateperone Tosylate Brand 17 $42,487
Trintellix Vortioxetine Hydrobromide Brand 52 $30,230
Vyvanse Lisdexamfetamine Dimesylate Brand 31 $13,383
Risperidone Er Risperidone Microspheres Brand 12 $11,774
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 186 $6,460
Aripiprazole Generic 165 $6,304
Lisdexamfetamine Dimesylate Generic 27 $5,164
Duloxetine Hcl Generic 182 $4,315

The 10 drugs with the highest cost, of 55 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$23,549

Medicare's payments for the services billed

Medicare patients

102

Average age 66

Services billed

320

69 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 71%
High blood pressure 54%
Arthritis 45%
Ischemic heart disease 20%
Chronic kidney disease 18%
Diabetes 15%
Cancer 15%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $4,450
$4,450 119 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $2,725
$2,725 — —
Auvelity
  • Axsome Therapeutics, Inc. $276
$276 — —
Azstarys
  • Corium, Inc. $254
$254 — —
ARISTADA
  • Alkermes, Inc. $250
$250 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

595 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record